AMENDMENT

Kindly amend the claims, without prejudice, as follows:

In the claims:

1. (Currently Amended) A transdermal system for the delivery of clonidine consisting essentially of:

a pressure-sensitive contact adhesive layer ~~consisting of~~ comprising clonidine and a copolymer, wherein said copolymer consists of 2-ethylhexyl acrylate and vinyl acetate;

a covering; and

on a side opposite from the covering, a removable support that temporarily covers the contact adhesive layer.

16. (Previously Presented) The transdermal system of claim 1 wherein the contact adhesive layer comprises clonidine in a concentration range of from 0.1 to 20% by weight.

17. (Previously Presented) The transdermal system of claim 16 wherein the contact adhesive layer comprises clonidine in a concentration range of from 2 to 10% by weight.

18. (Previously Presented) The transdermal system of claim 1 wherein the contact adhesive layer further comprises at least one element selected form the group consisting of fillers, skin-protective substances, and tackifiers.

19. (Previously Presented) A transdermal system comprising a planar self-adhesive patch of a multi-layered structure consisting essentially of:

a clondine-containing, pressure–sensitive contact adhesive layer consisting of a copolymer consisting of the monomers 2-ethylhexyl acrylate and vinyl acetate;

a covering; and

on a side opposite from the covering a removable support that temporarily covers the contact adhesive layer.

20. (Cancelled).

21. (Previously Presented) The transdermal system of claim 19 wherein the covering is selected from the group consisting of plastic film, plastic foam, woven fabric, and non-woven fabric.

22. (Previously Presented) The transdermal system of claim 19 wherein the support is of plastic film, paper, or a laminate of plastic film and paper.

23. (Previously Presented) The transdermal system of claim 22 wherein the support is siliconized.

24. (Previously Presented) The transdermal system of claim 21 wherein the support comprises a polyester film, polyethylene film, or polypropylene film.

25. (Previously Presented) The transdermal system of claim 19 wherein the contact adhesive layer has a dry weight per unit area of from 20 g/m^2 to 150 g/m^2.

26. (Previously Presented) The transdermal system of claim 25 wherein the contact adhesive layer has a dry weight per unit area of from 50 g/m^2 to 120 g/m^2.

27. (Previously Presented) The transdermal system of claim 1 wherein the delivery rate is from 10 μg to 1000 μg of clonidine per day.

28. (Previously Presented) The transdermal system of claim 1 wherein the delivery rate is from 50 μg to 500 μg of clonidine per day.

29. (Previously Presented) A method of treating a disorder selected from the group consisting of hypertension, migraine, anxiety states, hyperkinetic behavioral disorders, withdrawal symptoms in alcohol or drug withdrawal, and menopausal symptoms, said method comprising the step of administrating clonidine to a patient in need of such treatment by transdermal delivery from the transdermal system of claim 1.

30. (Previously Presented) A transdermal system for the delivery of clonidine consisting essentially of:

a pressure-sensitive contact adhesive layer consisting of clonidine and a copolymer, wherein said copolymer consists of 2-ethylhexyl acrylate and vinyl acetate;

a covering; and

on a side opposite from the covering, a removable support that temporarily covers the contact adhesive layer, wherein the concentration of said clonidine is in a range of from 0.1 to 20% by weight.